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Abstract
Background: Following remission of an anxiety disorder or 
a depressive disorder, antidepressants are frequently dis-
continued and in the case of symptom occurrence reinstat-
ed. Reinstatement of antidepressants seems less effective in 
some patients, but an overview is lacking. This systematic 
review aimed to provide insight into the magnitude and risk 
factors of response failure after reinstatement of antidepres-
sants in patients with anxiety disorders, depressive disor-
ders, obsessive-compulsive disorder (OCD), or posttraumat-
ic stress disorder (PTSD). Method: PubMed, Embase, and tri-
al registers were systematically searched for studies in which 
patients: (1) had an anxiety disorder, a depressive disorder, 
OCD, or PTSD and (2) experienced failure to respond after 
reinstatement of a previously effective antidepressant. Re-
sults: Ten studies reported failure to respond following anti-
depressant reinstatement. The phenomenon was observed 
in 16.5% of patients with a depressive disorder, OCD, and 
social phobia and occurred in all common classes of antide-
pressants. The range of response failure was broad, varying 
between 3.8 and 42.9% across studies. No risk factors for fail-
ure to respond were investigated. The overall study quality 
was limited. Conclusion: Research investigating response 
failure is scarce and the study quality limited. Response fail-
ure occurred in a substantial minority of patients. Contribu-
tors to the relevance of this phenomenon are the prevalence 
of the investigated disorders, the number of patients being 
treated with antidepressants, and the occurrence of re-
sponse failure for all common classes of antidepressants. 
This systematic review highlights the need for studies sys-
tematically investigating this phenomenon and associated 
risk factors. © 2018 The Author(s) 
Published by S. Karger AG, Basel
R.C.B. and R.C.W. contributed equally to this work.
This article is licensed under the Creative Commons Attribution-
NonCommercial-NoDerivatives 4.0 International License (CC BY-
NC-ND) (http://www.karger.com/Services/OpenAccessLicense). 
Usage and distribution for commercial purposes as well as any dis-
tribution of modified material requires written permission.
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Introduction
Antidepressant medication is used to treat up to two 
thirds of patients with anxiety and depressive disorders 
[1], with an increasing number of patients using antide-
pressants long term [2]. It is frequently assumed that the 
response to antidepressants in patients remains stable 
over time, but there are observations that this is not the 
case.
Firstly, during continuous treatment with an antide-
pressant the effect of the antidepressant may decrease [3–
7]. One study suggests that this “poop out” phenomenon 
is more prominent in selective serotonin reuptake inhib-
itors than in selective serotonin and noradrenalin reup-
take inhibitors and tricyclic antidepressants [6].
Secondly, the response to antidepressants may de-
crease with repeated exposure [8, 9]. Two clinical trials 
reported that in patients with major depressive disorder 
(MDD) or bipolar II disorder the number of previous ex-
posures to antidepressants was negatively related to the 
treatment response in a following trial with antidepres-
sants [8, 9]. Indications for this phenomenon were also 
found in the STAR*D trial, a naturalistic study investigat-
ing the response to antidepressants in successive treat-
ment steps [10]. It was found that the response to the first 
treatment step was lower in patients who had received 
previous treatment for the current episode compared to 
patients who had not received treatment for the current 
episode.
Thirdly, response failure can occur when an initially 
effective antidepressant is discontinued following symp-
tom remission and reinstated after the occurrence of 
symptoms. This situation frequently occurs in daily clin-
ical practice because: (1) anxiety and depressive disorders 
are highly prevalent [11], (2) up to two thirds of patients 
receive antidepressants [1], (3) many patients achieve re-
mission while on antidepressant medication [12–22], (4) 
treatment guidelines advise discontinuation after a peri-
od of sustained remission [12, 14–23], (5) and 36 or 41% 
of patients with, respectively, anxiety disorders or depres-
sive disorders experience symptoms following antide-
pressant discontinuation [24, 25]. These are often labelled 
as relapse, but according to Chouinard and Chouinard 
[26] these symptoms can also be explained as newly oc-
curring symptoms caused by the withdrawal of antide-
pressants. For these patients the effectiveness of antide-
pressants after reinstatement is of utmost importance. 
Unfortunately, there are indications that reinstatement of 
the same antidepressant after the occurrence of symp-
toms does not necessarily yield an effect similar to that in 
the period prior to drug discontinuation. Two case stud-
ies reported that with reinstatement of the same previ-
ously effective antidepressant the subsequent response 
was absent [27, 28].
Little is known, however, about this third type of re-
sponse failure. Although 2 literature reviews have been 
conducted [29, 30], no systematic review of failure to re-
spond to antidepressants after reinstatement of the same 
medicament has previously been published. Therefore, 
we systematically reviewed the available empirical litera-
ture focusing on failure to respond again to the same an-
tidepressants following reinstatement due to the occur-
rence of symptoms in patients with depressive disorder, 
anxiety disorders, obsessive-compulsive disorder (OCD), 
or posttraumatic stress disorder (PTSD).
Method
Literature Search
PubMed and Embase were searched (from inception to July 
2017) for empirical studies including adult (age ≥18 years) patients 
with an anxiety disorder, a depressive disorder, OCD, or PTSD 
who had an initial response to an antidepressant but after discon-
tinuation and later reinstatement of the same antidepressant expe-
rienced an ineffective or less effective response. Additionally, the 
reference lists of the included articles were screened and several 
trial registers were searched (i.e., Cochrane Library, Current Con-
trolled Trials, Clinical Trials, The Netherlands Trial Register, and 
NHS Centre for reviews and dissemination). Included were manu-
scripts containing original research data and English language 
publications only. Case studies and case series were excluded.
The used search string included terms referring to reinstate-
ment of treatment, anxiety disorders, depressive disorders, OCD, 
and PTSD and antidepressant medications (see online suppl. 1 for 
the complete search strategy; for all online suppl. material, see 
www.karger.com/doi/10.1159/000491550). The search was con-
ducted by an experienced librarian, R.C.B., and R.C.W. In accor-
dance with PRISMA guidelines [31, 32], the studies were selected 
by 2 independent reviewers (R.C.B. and R.C.W.). Firstly, studies 
were assessed for eligibility based on their title and abstract. Sec-
ondly, both reviewers assessed the full text of the selected articles. 
In case of disagreement, consensus was reached by referral to the 
text and discussion within the project group (R.C.B., R.C.W., 
N.M.B., and A.J.L.M.B.).
Data Extraction and Analysis
Data extraction forms were generated based on the Cochrane 
data collection form for clinical trials [33]. The following informa-
tion was extracted: study details (year of publication, country of 
study, single- or multi-center study), participant details (number 
of participants, inclusion and exclusion criteria, age, gender, type 
of disorder, comorbidity and number of previous episodes, num-
ber of participants with and without failure to respond), medica-
tion details (antidepressant type, class, dose, and frequency; dis-
continuation mode [abrupt vs. tapered], comedication), method-
ological details (study design, study duration, time points of 
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measurements, version of diagnostic tool, definitions of response, 
remission, and occurrence), information about the course of re-
sponse failure, and risk factors. R.C.B. and R.C.W. extracted data 
from half of the articles and then checked the other half of the data. 
Disagreements were solved by referral to the data.
Quality Assessment and Publication Bias
The quality of the studies was assessed using the Cochrane Col-
laboration tool [34]. Assessed aspects were related to the demo-
graphics and clinical characteristics of the population at reinstate-
ment, the treatment with antidepressants with an effect and the 
treatment with antidepressants with response failure, and poten-
tial confounders. R.C.B. did the initial scoring of the studies, and 
this was double-checked by R.C.W. In case of disagreement, con-
sensus was reached through discussion.
Results
Literature Search
The search of PubMed and Embase resulted in 10,850 
unique records; of these, 10,700 were excluded based on 
their title and abstract, resulting in 150 records for full-
text screening (online suppl. 2). We were unable to ac-
quire a full-text copy of 4 articles. Of the remaining 146 
records, 8 articles could be included [35–42]. The search 
of the reference lists of the included articles resulted in 
the additional inclusion of 2 articles [43, 44]. No addi-
tional records were included based on the search of tri-
al registers. This systematic review thus contains 10 
studies.
Study Characteristics
Online supplement 3 provides an overview of the 
characteristics of the 10 included studies. The studies 
were published between 1989 and 2006 and consisted of 
1 retrospective chart review [42] and 9 prospective stud-
ies with reinstatement after the occurrence of symptoms 
[35–41, 43, 44]. Most prospective studies [36–41, 43, 44] 
were not placebo controlled. The sample sizes in the re-
instatement phase ranged from 11 to 81 participants. 
Response and/or remission at reinstatement was de-
fined in varying ways across studies (online suppl. 4). 
Failure to respond has been reported in patients diag-
nosed with MDD and/or dysthymia [35–38, 41–44], 
OCD [39], and social phobia [40]. We did not find stud-
ies regarding other anxiety disorders (e.g., generalized 
anxiety disorder, panic disorder, specific phobia) or re-
garding PTSD.
From online supplement 3 it appears that failure to re-
spond was reported in 16.5% of patients restarting an an-
tidepressant (394 exposures leading to 65 patients with 
response failure). The range across studies reporting fail-
ure to respond was broad, ranging from 3.8 to 42.9%. In 
1 study the patients did not have any previous episodes 
[37], while in 2 studies the patients had had at least 1 pre-
vious episode prior to study baseline [41, 42], and in 1 
study the patients had had at least 3 previous episodes 
[43]. The other 6 studies did not report whether the pa-
tients had experienced prior episodes [35, 36, 38–40, 44]. 
Failure to respond following reinstatement has been ob-
served for monoamine oxidase inhibitors [37, 40], tricy-
clic antidepressants [37–39, 41–44], selective serotonin 
reuptake inhibitors [35, 39], and selective serotonin and 
noradrenalin reuptake inhibitors [36] and thus in all 
common classes of antidepressants. Apart from the study 
of Flint and Rifat [37], no studies reported on comedica-
tion (online suppl. 3).
Depressive Disorders
Following open-label treatment, 6 studies prospective-
ly followed participants diagnosed with MDD [35–37, 41, 
43, 44] and 1 study followed patients with pure dysthymia 
or dysthymia with MDD [38] (online suppl. 3). These 
studies included 21–501 patients with response to antide-
pressant treatment of the index disorder, and 11–58 of 
those patients received retreatment following the occur-
rence of symptoms. Response failure occurred in patients 
treated with desipramine (n = 2 [8.3%], 200 mg/day [44], 
and n = 1 [8.3%], 75–300 mg/day, with plasma levels 
ranging from 150 to 300 ng/mL [38]), imipramine (n = 7 
[18.9%], median dose 200 mg/day, with a median plasma 
level of 300 ng/mL [43]), nortriptyline (n = 3 [10.0%], 
mean dose 80.4 mg/day, plasma level 95.1 ng/mL [41]), 
fluoxetine (n = 6 [10.9%], 20 mg/day [35]), and dulox-
etine (n = 15 [26.3%], 60 mg/day [36]). One study [37] 
reported response failure after reinstatement of nortrip-
tyline or phenelzine corresponding to what patients had 
previously received (n = 1 [9.1%]), but it did not specify 
the dosage or the antidepressant. In 3 studies patients si-
multaneously received psychological treatment and anti-
depressant treatment for their symptoms [41, 43, 44]. Fol-
lowing the occurrence of symptoms, psychological treat-
ment and antidepressant treatment were both reinstated 
in 2 of the 3 studies [41, 43].
In addition to these 7 prospective follow-up studies, 1 
study consisted of a retrospective chart review [42] (on-
line suppl. 3). Based on the medical records of patients 
with MDD it was found that, of the 35 patients who re-
ceived the same antidepressant medication and dose as in 
the previous episode, 15 (42.9%) no longer responded 
[42].
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Anxiety Disorders
One study [40] investigated the long-term treatment 
outcomes of moclobemide (mean dose 730 mg/day) for 
social phobia (online suppl. 3). In that prospective study, 
patients were treated for 2 years followed by a no-treat-
ment period of at least 1 month. When a patient experi-
enced occurrence of symptoms, treatment was reinstated 
for another 2 years, again followed by a no-treatment pe-
riod of at least 1 month. Of the patients (n = 51) who were 
retreated with moclobemide for 9 months, 2 (3.8%) no 
longer responded.
Obsessive-Compulsive Disorder
One study reported on failure to respond after rein-
statement of antidepressants in OCD [39], using a pro-
spective design to assess whether patients with OCD had 
a similarly effective response after the same drug was re-
instated following the occurrence of symptoms (online 
suppl. 3). They found that out of the 81 patients who ex-
perienced occurrence of symptoms and were retreated 
with clomipramine (150 mg/day), fluoxetine (40 mg/
day), fluvoxamine (300 mg/day), or paroxetine (40 mg/
day), 13 (16.0%) had an ineffective or less effective re-
sponse when retreated with the same drug at the same 
dose compared to the initial trial. No differences were ob-
served for the different drugs [39].
Risk Factors
None of the included studies investigated risk factors 
for response failure to antidepressant medication.
Quality Assessment and Publication Bias
In all of the studies information was missing to some 
extent, though the amount of missing information varied 
between studies (online suppl. 5). Demographic informa-
tion was missing in 3 studies [37, 39, 42]. One study only 
reported information about the baseline population [40] 
but not specifically about the group in which antidepres-
sants were reinstated. In most studies it was difficult to 
determine whether antidepressant treatment and rein-
statement were adequately administered. Information 
was missing about which specific antidepressant had 
been used in treatment [42], for which antidepressant 
failure to respond had occurred [37, 42], the dose and fre-
quency of antidepressant treatment and reinstatement 
[37, 42], the duration of the treatment [37, 41–44], the 
duration of reinstatement [37, 38, 41–44], and the plasma 
levels of tricyclic antidepressants during treatment and/
or reinstatement [37–39, 42, 44].
Several types of bias may also be present (online suppl. 
5). Reporting bias could have occurred as most studies are 
subgroup analyses of a larger study [35–39, 44–46] and it 
is not reported how these subsamples corresponded to 
the overall sample in terms of numbers and/or character-
istics. In 3 studies it was also not clear which participants 
were included in the statistical analyses of the reinstate-
ment phase [36, 40, 44], which could have resulted in ei-
ther underestimation or overestimation of the number of 
patients with response failure. Bias could also have been 
introduced due to inadequate blinding of patients, prac-
titioners, and/or outcome assessors in most studies and 
thus outcome expectancies could have influenced the re-
sults. This can result in overestimation of the effect of 
treatment [47, 48], and as thus reinstatement of antide-
pressants may have been considered more effective in pa-
tients than it actually was, thereby underestimating the 
proportion of response failure. Moreover, the study out-
comes could have been affected by the allowance of co-
medication [37] and psychotherapy [41, 43, 44] or by not 
excluding comorbid disorders [40, 41].
Discussion
The aim of this systematic review was to provide an 
overview of empirical literature reporting failure to re-
spond after reinstatement of antidepressant medication 
that was previously effective in patients with depressive 
disorder, anxiety disorder, OCD, or PTSD. The results 
showed that 16.5% (range 3.8–42.9%) of the patients ex-
perience failure to respond and this occurred in all class-
es of antidepressants. This phenomenon is thereby clini-
cally relevant.
Our review suggests that a stable response to antide-
pressants after reinstatement cannot be assumed in all pa-
tients. Given that a decrease in the effect of antidepres-
sants has also been reported during continuous antide-
pressant use [3–7], with repeated exposures [8–10], and 
in patients with recurrent episodes [49], it is possible that 
these different types of response failures reflect a broader 
phenomenon. Therefore, it is important to investigate 
which mechanisms underlie response failure to antide-
pressants and whether the core mechanisms are similar 
for all of the aforementioned varieties of response failure.
The included studies proposed some possible pharma-
codynamic mechanisms. Three studies suggested that pa-
tients who no longer responded were initially placebo re-
sponders and thus never had a “true” drug response [35, 
39, 44]. This hypothesis was, however, disregarded by 
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Maina et al. [39], who considered it unlikely that a pla-
cebo response existed for the entire duration of the 
6-month treatment phase. An alternative hypothesis, 
suggested by 2 studies [35, 44], was that patients had de-
veloped a “tolerance” to antidepressants over time and 
therefore did not respond anymore after reinstatement. 
Since the possible underlying pharmacological mecha-
nisms were not explained by the authors and have not 
been studied systematically, they remain speculative.
Moreover, response failure could also be the result of 
progression of the disease [39, 42]. For depressive disor-
ders, it is known that with an increasing number of epi-
sodes the likelihood of symptom occurrence also increas-
es [50–53], potentially resulting in a chronic course with 
a more severe symptomatology [54]. Thus, the effective-
ness of the antidepressants may remain unchanged, but 
the underlying disorder may become more severe and can 
no longer be effectively treated. It is difficult to determine 
if this is a relevant factor in the present study because 6 of 
the 10 included studies did not report the duration of the 
index disorder or the number of previous episodes. In the 
studies that reported on duration, there were no clear in-
dications of a relationship between duration or number 
of previous episodes and failure to respond. One study 
reported that patients had no previous episodes [37], and 
2 other studies reported that patients had at least 1 previ-
ous episode [41, 42]. Only 1 study included patients with 
multiple previous episodes (mean 6.2) [43]. The propor-
tion of response failure across these studies were 9.1 [37], 
42.9 [42], 10 [41], and 18.9% [43], respectively. An argu-
ment in favor of this disease progression hypothesis is 
that the proportion of response failure seems to be com-
parable to occurrence rates during maintenance treat-
ment [24, 25]. However, since there is no direct compar-
ison with maintenance therapy, the studies included in 
this review cannot substantiate this hypothesis.
Although the underlying mechanisms are still unclear, 
it is important to consider a possible harmful role of an-
tidepressants in the process of response failure. The op-
positional model of tolerance states that it cannot be ex-
cluded that antidepressants have a detrimental effect on 
the course of illness in anxiety disorders and depressive 
disorders [29, 30]. According to this model, “continued 
drug treatment may recruit processes that oppose the ini-
tial acute effects of a drug and may result in failure to re-
spond” [p. 127 in 29], which may explain response failure 
following reinstatement of the initial effective antidepres-
sant. The model further states that “continued antide-
pressant treatment may also propel the illness to a more 
malignant and treatment-unresponsive course” and that 
following discontinuation “oppositional processes may 
operate for some time, resulting in withdrawal symp-
toms, and increased vulnerability to relapse or resistance 
when treatment is reinitiated” [29, p. 127]. These poten-
tial iatrogenic effects of antidepressants should be further 
examined, especially because long-term antidepressant 
use is increasing [2].
Failure to respond could also result from transition of 
the index disorder to another disorder. In patients with 
MDD who are resistant to antidepressant treatment, the 
diagnosis is more frequently changed from MDD to bi-
polar disorder compared to patients without antidepres-
sant resistance [55]. Transition from MDD to bipolar dis-
order does not explain why response failure is also ob-
served in OCD and social phobia, and the time span of 
the included studies is to limited for observation of tran-
sition.
In addition to pharmacodynamic mechanisms and 
disease-related factors, changes in the pharmacokinetics 
of antidepressant drugs over time may contribute to re-
sponse failure during subsequent episodes of depression 
or anxiety. Specifically, an increased drug metabolism in 
subsequent episodes compared to the index episode can 
reduce plasma drug concentrations and, as a conse-
quence, drug efficacy. Cytochrome P450 (CYP) induc-
tion related to comedication or other factors like smoking 
could influence drug metabolism and is particularly rel-
evant to antidepressant drugs metabolized by CYP3A4, 
CYP1A2, CYP2C9, and CYP2C19 [56]. Most of the in-
cluded antidepressants associated with a failure to re-
spond are primarily metabolized by CYP2D6. Since 
CYP2D6 is generally accepted to not be inducible [57], 
pharmacokinetic changes are not expected to contribute 
substantially to subsequent response failure to antide-
pressant drugs.
To our knowledge, this is the first review that specifi-
cally investigates failure to respond following reinstate-
ment of an antidepressant after successful treatment for 
the same disorder with a systematic approach. A major 
strength of this review is that we conducted a broad lit-
erature search, checked the reference lists of the included 
studies, and searched trial registers for relevant studies. 
Therefore, it is probable that we captured most of the 
available literature on this topic. The results of this sys-
tematic review should, however, be interpreted in the 
context of the following limitations.
The included studies consist of 9 prospective studies 
with reinstatement after the occurrence of symptoms and 
1 retrospective chart review. These are nonsystematic 
studies with methodological inconsistencies. Across 
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studies different definitions for response failure were 
used, limiting the comparability of the studies. Also, in 
studies that provided simultaneous antidepressant and 
psychological treatments, the independent effects of these 
treatments could not be untangled in either the initial 
phase or the reinstatement phase. As a result, this could 
have led to underestimation of the number of nonre-
sponding patients.
Furthermore, none of the included studies reported 
any risk factors for response failure. Consequently, it re-
mains unknown which patients are potentially at risk and 
which patients can restart antidepressants in a relatively 
unproblematic manner following the occurrence of 
symptoms. Additionally, whether response failure also 
occurs in more recently introduced antidepressants is un-
known, as the most recently published study in this sys-
tematic review is from 2006. Moreover, because the in-
cluded studies were of low to moderate quality and bias 
may be present, no firm conclusion can be drawn. These 
limitations highlight the need for up-to-date good-quali-
ty research.
In recent years some attention has been paid to re-
sponse failure [58]. This systematic review shows, how-
ever, that the phenomenon is largely understudied and 
consists of older studies (from 2006 and earlier) and that 
the majority of studies conducted are of low to moderate 
quality.
Although a failure to respond only seems to occur in a 
minority of patients restarting antidepressants (16.5%, 
range 3.8–42.9%), it is of clinical relevance given the high 
number of patients taking antidepressants [1], the occur-
rence of the phenomenon in all common classes of anti-
depressants, the high prevalence of anxiety disorders, de-
pressive disorders, OCD, and PTSD [11], and the ten-
dency of these disorders to run a chronic course in which 
the occurrence of symptoms is common [24, 25, 54, 59–
67, 68–70].
This systematic review identified the need for high-
quality studies investigating the phenomenon of response 
failure. The European Medicines Agency (EMA) current-
ly requires that medication trials for anxiety disorders, 
depressive disorders, OCD, and PTSD have a placebo-
controlled continuation phase varying between 6 and 12 
months of follow-up [71–76]. To increase our under-
standing of the phenomenon and its etiology and to better 
advise patients, response failure after reinstatement 
should be compared to response failure during mainte-
nance therapy. A first recommendation might be that pla-
cebo-controlled discontinuation trials also investigate to 
what extent patients who switch to the placebo-arm and 
experience occurrence of symptoms respond again to the 
medication under study. This will result in more system-
atic research in a larger population, insight into the oc-
currence of response failure in other disorders or in re-
cently developed medications, and determination of pos-
sible risk factors. Additionally, investigation of underlying 
mechanisms of failure to respond is recommended. When 
patients at risk for response failure after reinstatement 
can be identified in the future, personalized treatment ad-
vice can be given in order to improve the long-term prog-
nosis of the patients.
Acknowledgment
We thank Caroline Planting and Jopie van der Spek of the Am-
sterdam UMC, Vrije Universiteit Amsterdam library for their help 
with conduction of the literature search.
References
 1 ESEMeD/MHEDEA 2000 investigators; Alon-
so J, Angermeyer MC, Bernert S, Bruffaerts R, 
Brugha TS, Bryson H, Girolamo G, de Graaf R, 
Demyttenaere K, Gasquet I, Haro JM, Katz SJ, 
Kessler RC, Kovess V, Lepine JP, Ormel J, Poli-
dori G, Russo LJ, Vilagut G, Almansa J, Arb-
abzadeh-Bouchez S, Autonell J, Bernal M, 
Buist-Bouwman MA, Codony M, Domingo-
Salvany A, Ferrer M, Joo SS, Martinez-Alonso 
M, Matschinger H, Mazzi F, Morgan Z, Moro-
sini P, Palacin C, Romera B, Taub N, Volle-
bergh WAM: Use of mental health services in 
Europe: results from the European Study of the 
Epidemiology of Mental Disorders (ESEMeD) 
project. Acta Psychiatr Scand 2004; 109: 47–54.
 2 Huijbregts KM, Hoogendoorn A, Slottje P, 
van Balkom AJLM, Batelaan NM: Long-term 
and short-term antidepressant use in general 
practice: data from a large cohort in The 
Netherlands. Psychother Psychosom 2017; 86: 
362–369.
 3 Bockting CLH, ten Doesschate MC, Spijker J, 
Spinhoven P, Koeter MWJ, Schene AH; DEL-
TA study group: Continuation and mainte-
nance use of antidepressants in recurrent de-
pression. Psychother Psychosom 2008; 77: 
17–26.
 4 Byrne SE, Rothschild AJ: Loss of antidepres-
sant efficacy during maintenance therapy: 
possible mechanisms and treatments. J Clin 
Psychiatry 1998; 59: 279–288.
 5 Fava M, Rappe SM, Pava JA, Nierenberg AA, 
Alpert JE, Rosenbaum JF: Relapse in patients 
on long-term fluoxetine treatment: response 
to increased fluoxetine dose. J Clin Psychiatry 
1995; 56: 52–55.
 6 Posternak MA, Zimmerman M: Dual reup-
take inhibitors incur lower rates of tachyphy-
laxis than selective serotonin reuptake inhibi-
tors: a retrospective study. J Clin Psychiatry 
2005; 66: 705–707.
Response Failure in Antidepressants 7Psychother Psychosom
DOI: 10.1159/000491550
 7 Quitkin FM, Stewart JW, McGrath PJ, Nunes 
E, Ocepek-Welikson K, Tricamo E, Rabkin 
JG, Ross D, Klein DF: Loss of drug effects dur-
ing continuation therapy. Am J Psychiatry 
1993; 150: 562–565.
 8 Amsterdam JD, Williams D, Michelson D, 
Adler LA, Dunner DL, Nierenberg AA, Reim-
herr FW, Schatzberg AF: Tachyphylaxis after 
repeated antidepressant drug exposure in pa-
tients with recurrent major depressive disor-
der. Neuropsychobiology 2009; 59: 227–233.
 9 Leykin Y, Amsterdam JD, DeRubeis RJ, Gal-
lop R, Shelton RC, Hollon SD: Progressive re-
sistance to a selective serotonin reuptake in-
hibitor but not to cognitive therapy in the 
treatment of major depression. J Consult Clin 
Psychol 2007; 75: 267–276.
10 Rush AJ, Trivedi MH, Wisniewski SR, Nie-
renberg AA, Stewart JW, Warden D, Niedere-
he G, Thase ME, Lavori PW, Lebowitz BD, 
McGrath PJ, Rosenbaum JF, Sackeim HA, 
Kupfer DJ, Luther J, Fava M: Acute and lon-
ger-term outcomes in depressed outpatients 
requiring one or several treatment steps: a 
STAR*D report. Am J Psychiatry 2006; 163: 
1905–1917.
11 Kessler RC, Petukhova M, Sampson NA, 
Zaslavsky AM, Wittchen H-U: Twelve-
month and lifetime prevalence and lifetime 
morbid risk of anxiety and mood disorders in 
the United States: anxiety and mood disorders 
in the United States. Int J Methods Psychiatr 
Res 2012; 21: 169–184.
12 Bandelow B, Zohar J, Hollander E, Kasper S, 
Möller H-J, et al: World Federation of Societ-
ies of Biological Psychiatry (WFSBP) guide-
lines for the pharmacological treatment of 
anxiety, obsessive-compulsive and post-trau-
matic stress disorders: first revision. World J 
Biol Psychiatry 2008; 9: 248–312.
13 Bauer M, Pfennig A, Severus E, Whybrow PC, 
Angst J, Möller H-J; World Federation of So-
cieties of Biological Psychiatry; Task Force on 
Unipolar Depressive Disorders: World Fed-
eration of Societies of Biological Psychiatry 
(WFSBP) guidelines for biological treatment 
of unipolar depressive disorders. 1. Update 
2013 on the acute and continuation treatment 
of unipolar depressive disorders. World J Biol 
Psychiatry 2013; 14: 334–385.
14 Hassink-Franke L, Terluin B, van Heest F, 
Hekman J, van Marwijk HWJ, van Avendonk 
M: Standaard Angst (tweede herziening): 




15 National Institute for Health and Clinical Ex-
cellence: Obsessive-compulsive disorder and 
body dysmorphic disorder: treatment. 2005. 
http://www.nice.org.uk/guidance/cg31 (ac-
cessed January 4, 2016).
16 National Institute for Health and Clinical Ex-
cellence: Post-traumatic stress disorder: man-
agement. 2005. http://www.nice.org.uk/guid-
ance/cg26 (accessed January 4, 2016).
17 National Institute for Health and Clinical 
Excellence: Depression in adults: recognition 
and management. 2009. http://www.nice.org.
uk/guidance/cg90 (accessed January 4, 2016).
18 National Institute for Health and Clinical 
Excellence: Generalised anxiety disorder and 
panic disorder (with or without agoraphobia) 
in adults: management in primary, secondary 
and community care. 2011. http://www.nice.
org.uk/guidance/cg113 (accessed January 4, 
2016).
19 National Institute for Health and Clinical Ex-
cellence: Social anxiety disorder: recognition, 
assessment and treatment. 2013. http://www.
nice.org.uk/guidance/cg159 (accessed Janu-
ary 4, 2016).
20 Spijker J, Bockting CLH, Meeuwissen J, van 
Vliet I, Emmelkamp PMG, Hermens M, van 
Balkom AJ: Multidiciplinaire richtlijn de-
pressie (derde revisie): richtlijn voor de diag-
nostiek, behandeling en begeleiding van vol-
wassen patiënten met een depressive stoornis. 
Utrecht, Trimbos-instituut, 2013.
21 van Balkom AJLM, van Vliet I, Emmelkamp 
PMG, Bockting CLH, Spijker J, Hermens M, 
Meeuwissen J: Multidiciplinaire richtlijnen 
angststoornissen (derde revisie): richtlijn 
voor de diagnostiek, behandeling en be-
geleiding van volwassen patiënten met een 
angststoornis. Utrecht, Trimbos-instituut, 
2013.
22 van Weel-Baumgarten E, van Gelderen M, 
Grundmeijer HGLM, Licht-Strunk E, van 
Marwijk HWJ, van Rijswijk H, Tjaden B, Ver-
duijn M, Wiersma T, Burgers J, van Aven-
donk M, van der Weele G: NHG-Standaard 
Depressie (tweede herziening): Nederlands 




23 Bauer M, Severus E, Köhler S, Whybrow PC, 
Angst J, Möller H-J; WFSBP Task Force on 
Treatment Guidelines for Unipolar Depres-
sive Disorders: World Federation of Societies 
of Biological Psychiatry (WFSBP) guidelines 
for biological treatment of unipolar depres-
sive disorders. 2. Maintenance treatment of 
major depressive disorder: update 2015. 
World J Biol Psychiatry 2015; 16: 76–95.
24 Geddes JR, Carney SM, Davies C, Furukawa 
TA, Kupfer DJ, Frank E, Goodwin GM: Re-
lapse prevention with antidepressant drug 
treatment in depressive disorders: a system-
atic review. Lancet 2003; 361: 653–661.
25 Batelaan NM, Bosman RC, Muntingh A, 
Scholten WD, Huijbregts KM, van Balkom 
AJLM: Risk of relapse after antidepressant 
discontinuation in anxiety disorders, obses-
sive-compulsive disorder, and post-traumatic 
stress disorder: systematic review and meta-
analysis of relapse prevention trials. BMJ 
2017;j3927.
26 Chouinard G, Chouinard V-A: New classifi-
cation of selective serotonin reuptake inhibi-
tor withdrawal. Psychother Psychosom 2015; 
84: 63–71.
27 Donaldson SR: Tolerance to phenelzine and 
subsequent refractory depression: three cases. 
J Clin Psychiatry 1989; 50: 33–35.
28 Paholpak S: Clomipramine-resistant, fluox-
etine-responsive obsessive compulsive disor-
der: a case report. J Med Assoc Thai 2002; 85: 
1135–1138.
29 Fava GA: Can long-term treatment with anti-
depressant drugs worsen the course of de-
pression? J Clin Psychiatry 2003; 64: 123–133.
30 Fava GA, Offidani E: The mechanisms of tol-
erance in antidepressant action. Prog Neuro-
psychopharmacol Biol Psychiatry 2011; 35: 
1593–1602.
31 Menzies D: Systematic reviews and meta-
analyses. Int J Tuberc Lung Dis 2011; 15: 582–
593.
32 Moher D, Liberati A, Tetzlaff J, Altman DG: 
Preferred reporting items for systematic re-
views and meta-analyses: the PRISMA state-
ment. J Clin Epidemiol 2009; 62: 1006–1012.
33 Cochrane Training: Data collection forms for 




34 Higgins JPT, Altman DG, Gotzsche PC, Juni 
P, Moher D, Oxman AD, Savovic J, Schulz KF, 
Weeks L, Sterne JA; Cochrane Bias Methods 
Group; Cochrane Statistical Methods Group: 
The Cochrane Collaboration’s tool for assess-
ing risk of bias in randomised trials. BMJ 
2011; 343:d5928–d5928.
35 Fava M, Schmidt ME, Zhang S, Gonzales J, 
Raute NJ, Judge R: Treatment approaches to 
major depressive disorder relapse. 2. Reinitia-
tion of antidepressant treatment. Psychother 
Psychosom 2002; 71: 195–199.
36 Fava M, Detke MJ, Balestrieri M, Wang F, 
Raskin J, Perahia D: Management of depres-
sion relapse: re-initiation of duloxetine treat-
ment or dose increase. J Psychiatr Res 2006; 
40: 328–336.
37 Flint AJ, Rifat SL: Recurrence of first-episode 
geriatric depression after discontinuation of 
maintenance antidepressants. Am J Psychia-
try 1999; 156: 943–945.
38 Friedman RA, Mitchell J, Kocsis JH: Retreat-
ment for relapse following desipramine dis-
continuation in dysthymia. Am J Psychiatry 
1995; 152: 926–928.
39 Maina G, Albert U, Bogetto F: Relapses after 
discontinuation of drug associated with in-
creased resistance to treatment in obsessive-
compulsive disorder. Int Clin Psychopharma-
col 2001; 16: 33–38.
40 Versiani M, Amrein R, Montgomery SA: So-
cial phobia: long-term treatment outcome 
and prediction of response: a moclobemide 
study. Int Clin Psychopharmacol 1997; 12: 
239–254.
41 Reynolds CF, Frank E, Perel JM, Miller MD, 
Cornes C, Rifai AH, Pollock BG, Mazumdar 
S, George CJ, Houck PR: Treatment of con-
secutive episodes of major depression in the 
elderly. Am J Psychiatry 1994; 151: 1740–1743.
Bosman et al.Psychother Psychosom8
DOI: 10.1159/000491550
42 Remillard AJ, Blackshaw SL, Dangor A: Dif-
ferential responses to a single antidepressant 
in recurrent episodes of major depression. 
Hosp Community Psychiatry 1994; 45: 359–
361.
43 Kupfer DJ, Frank E, Perel JM: The advantage 
of early treatment intervention in recurrent 
depression. Arch Gen Psychiatry 1989; 46: 
771–775.
44 Fava GA, Rafanelli C, Grandi S, Canestrari R, 
Morphy MA: Six-year outcome for cognitive 
behavioral treatment of residual symptoms in 
major depression. Am J Psychiatry 1998; 155: 
1443–1445.
45 Kupfer DJ: Management of recurrent depres-
sion. J Clin Psychiatry 1993; 54: 29–33, discus-
sion 34–35.
46 Reynolds CF, Dew MA, Pollock BG, Mulsant 
BH, Frank E, Miller MD, Houck PR, Mazum-
dar S, Butters MA, Stack JA, Schlernitzauer 
MA, Whyte EM, Gildengers A, Karp J, Lenze 
E, Szanto K, Bensasi S, Kupfer DJ: Mainte-
nance treatment of major depression in old 
age. N Engl J Med 2006; 354: 1130–1138.
47 Wood L, Egger M, Gluud LL, Schulz KF, Juni 
P, Altman DG, Gluud C, Martin RM, Wood 
AJG, Sterne JAC: Empirical evidence of bias 
in treatment effect estimates in controlled tri-
als with different interventions and outcomes: 
meta-epidemiological study. BMJ 2008; 336: 
601–605.
48 Pildal J, Hrobjartsson A, Jorgensen K, Hilden 
J, Altman D, Gotzsche P: Impact of allocation 
concealment on conclusions drawn from 
meta-analyses of randomized trials. Int J Epi-
demiol 2007; 36: 847–857.
49 Kaymaz N, van Os J, Loonen AJM, Nolen 
WA: Evidence that patients with single versus 
recurrent depressive episodes are differential-
ly sensitive to treatment discontinuation: a 
meta-analysis of placebo-controlled random-
ized trials. J Clin Psychiatry 2008; 69: 1423–
1436.
50 Judd LL: The clinical course of unipolar major 
depressive disorders. Arch Gen Psychiatry 
1997; 54: 989.
51 Kessing LV, Hansen MG, Andersen PK, 
Angst J: The predictive effect of episodes on 
the risk of recurrence in depressive and bipo-
lar disorders – a life-long perspective. Acta 
Psychiatr Scand 2004; 109: 339–344.
52 Bulloch A, Williams J, Lavorato D, Patten S: 
Recurrence of major depressive disorder epi-
sodes is strongly dependent on the number of 
previous episodes. Depress Anxiety 2014; 31: 
72–76.
53 Solomon DA: Multiple recurrences of major 
depressive disorder. Am J Psychiatry 2000; 
157: 229–233.
54 Rhebergen D, Lamers F, Spijker J, de Graaf R, 
Beekman ATF, Penninx BWJH: Course tra-
jectories of unipolar depressive disorders 
identified by latent class growth analysis. Psy-
chol Med 2012; 42: 1383–1396.
55 Li C-T, Bai Y-M, Huang Y-L, Chen Y-S, Chen 
T-J, Cheng J-Y, Su T-P: Association between 
antidepressant resistance in unipolar depres-
sion and subsequent bipolar disorder: cohort 
study. Br J Psychiatry 2012; 200: 45–51.
56 Lin JH: CYP induction-mediated drug inter-
actions: in vitro assessment and clinical impli-
cations. Pharm Res 2006; 23: 1089–1116.
57 Farmacotherapeutisch Kompas: Farmacoki-
netiek: interacties tijdens de verschillende ki-
netische processen. 2017. https://www.farma-
cotherapeutischkompas.nl/farmacologie/
farmacokinetiek (accessed November 15, 
2017).
58 Fava GA: Rational use of antidepressant 
drugs. Psychother Psychosom 2014; 83: 197–
204.
59 Batelaan NM, Rhebergen D, Spinhoven P, van 
Balkom AJLM, Penninx BWJH: Two-year 
course trajectories of anxiety disorders: do 
DSM classifications matter? J Clin Psychiatry 
2014; 75: 985–993.
60 Beesdo-Baum K, Knappe S, Fehm L, Höfler 
M, Lieb R, Hofmann SG, Wittchen H-U: The 
natural course of social anxiety disorder 
among adolescents and young adults: natural 
course of social anxiety disorder. Acta Psychi-
atr Scand 2012; 126: 411–425.
61 Bruce SE, Yonkers KA, Otto MW, Eisen JL, 
Weisberg RB, Pagano M, Shea MT, Keller 
MB: Influence of psychiatric comorbidity on 
recovery and recurrence in generalized anxi-
ety disorder, social phobia, and panic disor-
der: a 12-year prospective study. Am J Psy-
chiatry 2005; 162: 1179–1187.
62 Colman I, Ploubidis GB, Wadsworth MEJ, 
Jones PB, Croudace TJ: A longitudinal typol-
ogy of symptoms of depression and anxiety 
over the life course. Biol Psychiatry 2007; 62: 
1265–1271.
63 Francis JL, Weisberg RB, Dyck IR, Culpepper 
L, Smith K, Orlando Edelen M, Keller MB: 
Characteristics and course of panic disorder 
and panic disorder with agoraphobia in pri-
mary care patients. Prim Care Companion J 
Clin Psychiatry 2007; 9: 173–179.
64 Hendriks SM, Spijker J, Licht CMM, Beek-
man ATF, Penninx BWJH: Two-year course 
of anxiety disorders: different across disor-
ders or dimensions? Acta Psychiatr Scand 
2013; 128: 212–221.
65 Keller MB: Social anxiety disorder clinical 
course and outcome: review of Harvard/
Brown Anxiety Research Project (HARP) 
findings. J Clin Psychiatry 2006; 67(suppl 12): 
14–19.
66 Nay W, Brown R, Roberson-Nay R: Longitu-
dinal course of panic disorder with and with-
out agoraphobia using the National Epidemi-
ologic Survey on Alcohol and Related Condi-
tions (NESARC). Psychiatry Res 2013; 208: 
54–61.
67 Olino TM, Klein DN, Lewinsohn PM, Rohde 
P, Seeley JR: Latent trajectory classes of de-
pressive and anxiety disorders from adoles-
cence to adulthood: descriptions of classes 
and associations with risk factors. Compr 
Psychiatry 2010; 51: 224–235.
68 Skipstein A, Janson H, Stoolmiller M, Mathie-
sen KS: Trajectories of maternal symptoms of 
anxiety and depression: a 13-year longitudi-
nal study of a population-based sample. BMC 
Public Health 2010; 10: 589.
69 Stoolmiller M, Kim HK, Capaldi DM: The 
course of depressive symptoms in men from 
early adolescence to young adulthood: identi-
fying latent trajectories and early predictors. J 
Abnorm Psychol 2005; 114: 331–345.
70 Yonkers KA, Bruce SE, Dyck IR, Keller MB: 
Chronicity, relapse, and illness: course of pan-
ic disorder, social phobia, and generalized 
anxiety disorder – findings in men and wom-
en from 8 years of follow-up. Depress Anxiety 
2003; 17: 173–179.
71 European Medicines Agency: Guideline on 
clinical investigation of medicinal products in 
the treatment of depression. 2013. http://
www.ema.europa.eu/docs/en_GB/docu-
ment_library/Scientific_guideline/2013/05/
WC500143770.pdf (accessed September 19, 
2017).
72 European Medicines Agency: Clinical investi-
gation of medicinal products for the treat-
ment of obsessive compulsive disorder. 2005. 
http://www.ema.europa.eu/docs/en_GB/
document_ l ibrary/Sc ient i f i c_guide-
line/2009/09/WC500003512.pdf (accessed 
September 19, 2017).
73 European Medicines Agency: Clinical investi-
gation of medicinal products indicated for 
generalised anxiety disorder. 2005. http://
www.ema.europa.eu/docs/en_GB/docu-
ment_library/Scientific_guideline/2009/09/
WC500003510.pdf (accessed September 19, 
2017).
74 European Medicines Agency: Clinical investi-
gation of medicinal products indicated for 
panic disorder. 2005. http://www.ema.euro-
pa.eu/docs/en_GB/document_library/Scien-
tific_guideline/2009/09/WC500003511.pdf 
(accessed September 19, 2017).
75 European Medicines Agency: Clinical investi-
gation of medicinal products indicated for the 
treatment of social anxiety. 2006. http://www.
ema.europa.eu/docs/en_GB/document_li-
brary/Sc ient i f i c_guide l ine/2009/09/
WC500003490.pdf (accessed September 19, 
2017).
76 European Medicines Agency: Development 
of medicinal products for the treatment of 
post-traumatic stress disorder. 2008. http://
www.ema.europa.eu/docs/en_GB/docu-
ment_library/Scientific_guideline/2009/09/
WC500003489.pdf (accessed September 19, 
2017).
